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Abstract
Introduction: There is an urgent need for novel agents to manage serious bacterial infections, particularly those contracted in healthcare
facilities. Tigecycline is a novel broad-spectrum glycylcycline with good activity against Gram-positive, many Gram-negative, anaerobic,
and some atypical pathogens that has been developed to address this need.
Aims: To review the evidence for the use of tigecycline in serious and complicated skin and soft tissue and intraabdominal infections.
Evidence review: There is substantial evidence that tigecycline is as effective as vancomycin plus aztreonam in complicated skin and
skin structure infections (SSSIs) and as effective as imipenem plus cilastatin in intraabdominal infections. Limited evidence shows
effectiveness in patients with resistant Acinetobacter infection in an intensive care unit, and the possibility that the use of tigecycline may
reduce length of hospital stay. The drug is well tolerated, with nausea and vomiting as the major adverse effects.
Outcomes summary: The introduction of tigecycline should be beneficial at a time of increasing problems with bacterial resistance, and
evidence to date has been sufficient for regulatory approval for complicated SSSIs and intraabdominal infections. Research into
tigecycline’s efficacy in other infectious diseases (notably pneumonia and bacteremia) is ongoing. Further good quality studies and
ongoing surveillance for any emerging bacterial resistance will be needed to determine outcomes with tigecycline relative to other novel
antibacterial agents, and to explore the economic implications of its adoption.
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Outcome measure Evidence Implications
Patient-oriented evidence
Good patient acceptability Substantial Good chance of success in severe infections without poor tolerability characteristic of
some older antibacterials
Avoidance of morbidity or mortality due to empiric
treatment failure in the most seriously ill patients
Limited Patients needing intensive care and/or infected with multiresistant pathogenic strains
resistant to other available antibacterials may respond to tigecycline. Further studies
required
Disease-oriented evidence
Clinical cure in complicated skin and soft tissue and
intraabdominal infections
Substantial Effective in these infections, but superiority over other antibacterials in terms of response
rates has not yet been demonstrated
Microbiologic eradication in patients infected with a
range of Gram-positive and Gram-negative
organisms
Substantial Is likely to be widely effective in a range of patients with serious and difficult infections
resistant to other agents
Economic evidence
More rapid discharge from hospital Limited Has considerable implications for both patient wellbeing and health economics; level 2
evidence required
Acquisition cost offset or incremental cost
effectiveness/benefit
No evidence Dependent on maintenance of clinical effectiveness and avoidance of empiric treatment
failure. Studies are required
Core evidence outcomes summary for tigecycline in complicated skin and soft tissue and
intraabdominal infectionsScope, aims, and objectives
This evidence-based review of the activity and clinical
effectiveness of tigecycline, the first of the novel glycylcycline
class of antibiotics, focuses on the use of the drug in complicated
and serious skin and soft tissue and intraabdominal infections
known to pose resistance problems with current therapy and
associated with or requiring treatment in healthcare facilities.
The emergence of microorganisms resistant to current
antibacterial agents is a matter of concern, particularly in patients
with serious, complicated, and nosocomial infections. Virtually all
common infectious bacteria have developed resistance to at least
one class of antibiotics, and tigecycline has been developed as
part of the effort to identify novel antibacterial agents in the face of
the growing problem, particularly in hospitals, of potentially life-
threatening multiresistant organisms and polymicrobial infections.
A number of agents are available for the treatment of conditions of
chief concern, including skin and intraabdominal infections
(particularly those contracted in hospitals) and pneumonia, but
available antibacterials have been widely affected by resistance,
and some older agents used for serious infections (e.g.
vancomycin) may be poorly tolerated by some patients. New
drugs that have recently been introduced into clinical practice
have been aimed mainly at multiresistant Gram-positive infections,
but early resistance to, for example, the novel oxazolidinone
linezolid (Mutnick et al. 2003; Halle et al. 2004; Meka et al. 2004)
and the cyclic lipopeptide daptomycin (Mangili et al. 2005; Sabol
et al. 2005) has already been reported. New agents that target
broad ranges of both Gram-positive and Gram-negative
organisms, particularly the emerging extended spectrum beta-
lactamase (ESBL) producers, anaerobes, and methicillin- and/or
oxacillin-resistant Gram-positive isolates, are urgently needed.
Tigecycline is one of a number of drugs under development with
these needs in mind, and is designed to circumvent two of the
most common resistance mechanisms, efflux and ribosomal
protection. It is a semisynthetic derivative of minocycline that is
mechanistically similar to the aminoglycosides, macrolides,
streptogramins, and oxazolidinones in that it binds to the 30S
ribosomal subunit (Chopra 2001; Guay 2004; Zhanel et al. 2004).
This blocks access of aminoacyl tRNA to its acceptor site and
leads to the prevention of bacterial protein synthesis and growth.
Examination and review of tigecycline is timely because, at the
time of writing, two phase III trials have been completed with
several others underway, and Food and Drug Administration
(FDA) approval has been granted in the USA (Anon. 2005).
Methods
The English language medical literature was searched for
appropriate articles relating to tigecycline. The following databases
were searched on June 16, 2005, and again on November 11, 2005,
with the search terms “tigecycline OR GAR-936,” and no date limits:
• PubMed, http://www.ncbi.nlm.nih.gov/entrez
• EMBASE and BIOSIS, http://www.datastarweb.com
• Database of Abstracts of Reviews of Effects (DARE), National
Health Service Economic Evaluation Database (NHSEED),
Health Technology Assessment (HTA),
http://www.york.ac.uk/inst/crd/crddatabases.htm
• Cochrane Database of Systematic Reviews (CDSR),
http://www.cochrane.org
• Clinical Evidence (BMJ), http://www.clinicalevidence.com
• National Institute for Health and Clinical Excellence (NICE),
http://www.nice.org.uk
• National Guidelines Clearing House, http://www.guideline.gov
The following websites were also searched for information
including details of recent meetings (since 2003) hosted by
societies specializing in medical microbiology:
• The annual congress of the European Society of Clinical
Microbiology and Infectious Diseases (ESCMID),
http://www.escmid.org
• The annual Interscience Conference on Antimicrobial Agents
and Chemotherapy (ICAAC), http://www.icaac.org
• The Federation of European Microbiological Societies (FEMS),
http://www.fems-microbiology.org
• The Infectious Diseases Society of America (IDSA),
http://www.idsociety.org
Table 1 summarizes the levels of evidence for articles identified
from the search strategy. The original search (June 2005) yielded
89 full papers, of which one was included as level 3 evidence. Two
of four level 2 studies were available in abstract form only at that
time. Updated searching (November 2005) yielded subsequent full
publications of these articles, together with one further paper and
an additional full report not included in the databases searched but
provided by the company developing tigecycline (Table 1).
There are currently no systematic reviews on tigecycline, and
there is a good deal of information on the drug that relates to its
antimicrobial activity in vitro and in animal models. These
references, together with nonsystematic general review articles in
which tigecycline featured, were excluded from the 132 full
papers identified. This left one fully published phase II study (level
3 evidence) and four phase III trials (level 2 evidence). Five studies
available as meetings abstracts were also identified (from
websites of major professional bodies and meetings as above) at
the time of writing. One of these provided level 3 (phase II)
evidence, one level 5 (a small case series from a single center),
and three were economic studies classified as level 3 evidence.
Disease overview
The development of tigecycline and other novel antibacterials
currently under investigation is aimed chiefly at the problems
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caused by resistant or complicated infections, with particular
emphasis on those contracted in healthcare facilities. It is worth
noting that, in the USA alone, nosocomial infections affect around
2 million persons admitted to hospitals for acute care each year
(Anon. 2000). Many of these infections are caused by
multiresistant Gram-positive and Gram-negative pathogens, and
their incidence continues to increase because of failure of hospital
hygiene procedures, selective pressures resulting from
inappropriate use and overuse of antibiotics, and other factors
that can lead to the encoding of bacterial resistance mechanisms.
The costs associated with managing infections are clearly
considerable. While it is difficult to estimate the global burden on
healthcare systems of infective disease, some helpful indicators
were provided in the 1990s by the UK Public Health Laboratory
Service (Plowman 2000), which examined the socioeconomic
consequences of hospital-acquired infection (HAI). Patients who
presented with one or more HAIs during an inpatient stay incurred
costs 2.9 times greater than those for uninfected patients. This
represented an absolute increase of £3154 per case in the
1449 patients selected for follow-up in this study. On average, the
length of hospital stay was 2.9 times (14 days) longer for patients
with an HAI, and additional burdens were imposed on community
healthcare services after discharge. The overall cost of HAIs to the
UK National Health Service was estimated as £986.36 million.
Diseases of particular concern include the frequently encountered
skin and skin structure infections (SSSIs) and intraabdominal
infections. SSSIs are caused chiefly by Gram-positive organisms,
and are increasing in incidence mainly because of aging of the
general population, increases in the numbers of critically ill and
immunocompromised patients, and the emergence of
multiresistant pathogens. SSSIs include simple and
uncomplicated or superficial infections such as erysipelas,
cellulitis, simple abscesses, furuncles, and wound infections, but
also encompass complicated and more serious disorders such as
necrotizing fasciitis, myositis, and gas gangrene. In general, an
SSSI is considered complicated if it involves structures beneath
the skin, such as fascia or muscle, requires significant surgical
intervention, or accompanies disorders such as diabetes mellitus
or human immunodeficiency virus (HIV) infection. Common
pathogens are Staphylococcus aureus, Streptococcus pyogenes,
Str. agalactiae, and group C and G streptococci [see the full
review on this subject by Raghavan & Linden (2004)].
Data from England and Wales indicate further the increasing
scale of the problem of multiresistant infections. Crowcroft and
Catchpole (2002) examined death registrations from 1993 to
1998 and found an increase in the proportion of certificates
mentioning methicillin-resistant Staph. aureus (MRSA) from 7.5%
in 1993 to 25% in 1998. The authors stated that improved rates
of reporting were unlikely to explain this increase, and found the
greatest rise in MRSA rates to be associated with death in which
invasive staphylococcal infection was given as the final
underlying cause.
Group D streptococci include the enterococci Enterococcus
faecalis, Ent. durans, and Ent. faecium; these microorganisms
cause endocarditis, urinary tract infections, intraabdominal
infections, cellulitis, wound infections, and bacteremia.
Enterococci are intrinsically resistant to many antimicrobial
agents including cephalosporins, penicillins, cotrimoxazole, and
clindamycin (Kauffman 2003). Since 1989, however, rapid
increases in the incidences of infection and colonization with
vancomycin-resistant enterococci (VRE) have been reported
(Anon. 1995). Increased risk of VRE infection is associated with
previous vancomycin or multiple antimicrobial therapy, severe
underlying disease, or abdominal surgery (Anon. 1995).
Enterococci can also be spread by direct or indirect contact
within institutions, and between hospitals by contaminated
personnel (Kauffman 2003).
Current therapy options
Although the treatment of complicated, resistant, and/or
nosocomial infections varies in accordance with national
recommendations and local infection control guidelines, generally
applicable prescribing information can be found in recent reviews
and official guidelines from the UK and USA. It is obviously not
possible to present a comprehensive review of current
antiinfective prescribing practice here, but a representative
picture can be drawn by focusing on the agents currently in use
for treating SSSIs and intraabdominal infections.
Current UK recommendations for skin and gastrointestinal
infections can be found in the British National Formulary, and are
summarized in Table 2 (BNF 2005). It should be noted that the
general principals of antibiotic prescribing apply in all cases:
benzyl- or phenoxymethylpenicillin is recommended for
streptococcal infection, with the addition of flucloxacillin where
staphylococcal infection is suspected, or a macrolide for atypical
infection (e.g. Mycoplasma or Chlamydia spp.). Topical mupirocin
may be effective against MRSA. Peritonitis and related infections
are covered generally by a cephalosporin or gentamicin with
metronidazole or clindamycin.
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Category Number of records
Full papers Abstracts
Initial search 132 74
records excluded 128 70
records included 4 4
Additional studies identified 11
Total records included 5 5
Level 1 clinical evidence 00
Level 2 clinical evidence 40
Level ≥3 clinical evidence 12
trials other than RCT 11
case studies 0 1
Economic evidence 03
For definition of levels of evidence, see Editorial Information on inside back cover.
RCT, randomized controlled trial.
Table 1 | Evidence base included in the reviewTigecycline | outcomes review
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Condition Recommended treatment
Skin infections
Cellulitis Benzylpenicillin + flucloxacillin (or erythromycin alone if penicillin-allergic)
Gastrointestinal system
Campylobacter enteritis Ciprofloxacin or erythromycin
Invasive salmonellosis Ciprofloxacin or trimethoprim
Shigellosis Ciprofloxacin or trimethoprim
Pseudomembranous colitis Metronidazole or vancomycin
Biliary tract infection Cephalosporin or gentamicin
Peritonitis Cephalosporin (or gentamicin) + metronidazole (or clindamycin)
Table 2 | UK prescribing recommendations for skin and gastrointestinal infections (BNF 2005)
Condition Recommended treatment
Skin and skin structure infections
Cellulitis or erysipelas Dicloxacillin, cephalexin, clindamycin, or erythromycin. Parenteral therapy in severely ill
patients/unable to take oral medication: nafcillin, cefazolin, clindamycin, or vancomycin
MRSA (hospital): linezolid, daptomycin or vancomycin. Also trimethoprim/sulfamethoxazole,
or quinolone with good Gram-positive activity
Necrotizing infections of skin, fascia, and muscle Mixed infection: ampicillin/sulbactam or piperacillin/tazobactam plus clindamycin plus ciprofloxacin.
Also imipenem/cilastatin, meropenem, ertapenem, or cefotaxime plus metronidazole or clindamycin
Streptococcal infection: penicillin plus clindamycin
Staphylococcus aureus: nafcillin, oxacillin, cefazolin, vancomycin, or clindamycin
Clostridial infection: clindamycin or penicillin
Surgical site infections Intestinal/genital tract, single agents: cefitoxin, ceftizoxime, ampicillin/sulbactam,
ticarcillin/clavulanate, piperacillin/tazobactam, imipenem/cilastatin, meropenem, or ertapenem
Intestinal/genital tract, combination: quinolone, third generation cephalosporin, aztreonam,
aminoglycoside (facultative and aerobic activity). Clindamycin, metronidazole, chloramphenicol,
penicillin + beta-lactamase inhibitor (anaerobic activity)
Nonintestinal: oxacillin, first generation cephalosporin (trunk and extremities). Cefoxitin,
ampicillin/sulbactam, other single agents as above for intestinal/genital operations (axillary or
perineal)
Intraabdominal infections
Mild to moderate community-acquired infections Ampicillin/sulbactam, cefazolin or cefuroxime/metronidazole, ticarcillin/clavulanate, or ertapenem
Healthcare-acquired infections Aminoglycoside (first choice for empiric use; completion with oral quinolone plus metronidazole or
oral amoxicillin/clavulanate)
Table 3 | Examples of US prescribing recommendations for skin and skin structure and intraabdominal infections (Solomkin et al.
2003; Stevens et al. 2005)
Comprehensive diagnostic and prescribing guidelines have been
published in the USA for SSSIs (Stevens et al. 2005) and
intraabdominal infections (Solomkin et al. 2003) by IDSA. Broadly, a
penicillinase-resistant semisynthetic penicillin or first generation
cephalosporin is recommended for cellulitis, with clindamycin or
vancomycin being suggested for patients allergic to penicillin. For
severe group A streptococcal and clostridial necrotizing infections,
parenteral clindamycin and penicillin therapy is recommended, with
a variety of single agents indicated for aerobic Gram-positive and
Gram-negative infections as well as for anaerobes (see Table 3).
SSSIs caused by community-acquired MRSA may be susceptible
to nonbeta-lactam antibiotics such as doxycycline, clindamycin,
trimethoprim/sulfamethoxazole, quinolones, or rifampicin. Severe
infections that require hospitalization and that have not responded
to other interventions can be treated with linezolid, daptomycin, or
vancomycin. Trimethoprim/sulfamethoxazole has also been used to
treat serious staphylococcal infections (Stevens et al. 2005).
Reviewers of recent developments in antiinfective therapy have
recommended antistaphylococcal penicillins (e.g. nafcillin,
oxacillin) or cefazolin for simple community-acquired SSSIs
(Raghavan & Linden 2004). Nosocomial infections, on the other
hand, may be treated with a semisynthetic penicillin such as
piperacillin/tazobactam with or without vancomycin or
teicoplanin. Vancomycin and teicoplanin are preferred for
suspected MRSA. Oral switching to linezolid can take place after185
early discharge of hospitalized patients with MRSA. Nosocomial
Gram-negative infections can be treated with an
antipseudomonal penicillin plus an aminoglycoside, and
carbapenems are recommended for ESBL-producing Gram-
negative pathogens (Raghavan & Linden 2004).
For patients with community-acquired intraabdominal infections,
IDSA recommends the use of agents with narrower spectra of
activity that are not commonly used for nosocomial infections.
These include ampicillin/sulbactam, cefazolin or cefuroxime plus
metronidazole, ticarcillin/clavulanate, ertapenem, and a quinolone
plus metronidazole. For patients with more serious infections,
alternatives include meropenem, imipenem/cilastatin, third or
fourth generation cephalosporins plus metronidazole,
ciprofloxacin plus metronidazole, or piperacillin/tazobactam (see
also Table 3). The more resistant flora associated with nosocomial
intraabdominal infections require treatment with more complex
multidrug regimens (Solomkin et al. 2003). It should be noted here
that these and other guidelines for antiinfective therapy are
subject to ongoing revision as novel agents are developed and
infection and resistance patterns change.
A number of novel antibacterial agents have been introduced in
recent years or are under current development. The major drugs
of interest are discussed in more detail in the following section
and are summarized in Table 4.
Unmet needs
Resistance to conventional antiinfective agents and the
continuing emergence of multiresistant organisms in healthcare
institutions are currently major concerns for researchers and
clinicians. Indeed, the IDSA is sufficiently worried about these
problems to have endorsed the introduction of legislation in the
US Senate to encourage the development of new antiinfectives,
and is currently urging its members to lobby Congress (IDSA
2005a). Key issues identified by IDSA include the “drying up of
the pipeline of new antibiotics,” and a loss of momentum in
antibiotic research because of cost and regulatory factors, time
constraints, and reduced profitability relative to other disease
areas (IDSA 2005b).
Epidemiologic data underline the reasons for these concerns.
High or intermediate resistance to penicillin is exhibited by 50%
of pneumococcal strains in the USA, and similar numbers of
Staph. aureus isolates are resistant to methicillin (Wenzel 2004).
Of the enterococci, 30% are resistant to vancomycin, and 20% of
strains of Pseudomonas aeruginosa are resistant to quinolones
and 15% to imipenem. A recent large survey of 670 US hospitals
has shown resistance rates for oxacillin-resistant Staph. aureus
(ORSA), VRE, quinolone-resistant Escherichia coli, and ESBL-
producing Klebsiella spp. to be 36, 10, 6, and 5%, respectively
(Diekema et al. 2004). These rates were reported to be on the
increase in the majority of hospitals.
Several research initiatives have been underway in recent years,
however, to identify new antiinfective agents. These efforts have
resulted in the introduction of a number of new drugs, most of
which are aimed at Gram-positive infections. These agents are
represented most prominently by the oxazolidinone linezolid and
the cyclic lipopeptide daptomycin.
Linezolid has a comprehensive spectrum of activity against the
major nosocomial Gram-positive pathogens, including those with
multiresistant phenotypes, and can be given either parenterally or
orally (Kauffman 2003; Raghavan & Linden 2004). However, as
mentioned above, early resistance to linezolid has already been
reported (Mutnick et al. 2003; Halle et al. 2004; Meka et al. 2004),
notably in staphylococcal and enterococcal isolates. Other
oxazolidinones are in early clinical development (Gravestock 2005).
Daptomycin has a mode of action that is not completely
understood but that involves cell membrane binding and
potassium efflux. The drug is rapidly bactericidal against most
Gram-positive pathogens, which may have importance in the
treatment of endocarditis and meningitis. Daptomycin has also
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Table 4 | Major new antimicrobial agents under development or recently introduced for nosocomial or resistant infections (adapted
from Raghavan & Linden 2004)
Drug Class Susceptible organisms Resistance
Linezolid Oxazolidinone MSSA, group A, B, C, F, G, and viridans Enterococcus faecium,
streptococci, CoNS, MRSA, GRSA, GISA, VRE, Staphylococcus aureus
VRSA, PRSP, corynebacteria, Listeria
Daptomycin Cyclic peptolide Ent. faecalis (vancomycin-susceptible), MSSA, Staph. aureus, Ent. faecalis
MRSA, Streptococcus agalactiae, Str. pyogenes
Quinupristin/dalfopristin Streptogramin MSSA, group A, B, C, F, G, and viridans streptococci,
CoNS, MRSA, GRSA, GISA, VRE, VRSA, PRSP,
Propionibacterium acne, clostridia, lactobacilli Ent. faecium, Staph. aureus
Ertapenem Carbapenem MSSA, Str. agalactiae, Str. pyogenes, MRSA, Str. agalactiae,  
Enterobacter spp. Str. pyogenes
Moxifloxacin and gatifloxacin Quinolone MSSA, CoNS, PRSP, group A, B, C, F, and G Staph. aureus
streptococci
Dalbavancin Glycopeptide MSSA, MRSA, VRE, CoNS, most streptococci, None to date
anaerobes
CoNS, coagulase-negative staphylococci; GISA, glycopeptide intermediate-resistant Staph. aureus; GRSA, glycopeptide-resistant Staph. aureus; MRSA, methicillin-resistant Staph. aureus;
MSSA, methicillin-sensitive Staph. aureus; PRSP, penicillin-resistant Str. pneumoniae; VRE, vancomycin-resistant enterococci; VRSA, vancomycin-resistant Staph. aureus.proven useful against SSSIs since its approval (Shah 2005), but
has no useful activity against Gram-negative organisms
(Strahilevitz & Rubinstein 2002).
Newer quinolones, including levofloxacin, moxifloxacin, and
gatifloxacin, have superior activity relative to ciprofloxacin against
respiratory Gram-positive pathogens (Abbanat et al. 2003), but
they do not cover MRSA, and may be compromised by cross-
resistance to older agents (Shah 2005). A number of novel
cephalosporins are in development; these have shown promising
activity against staphylococci but not against enterococci.
However, some of these agents have shown good activity against
Gram-negative pathogens such as Haemophilus influenzae and
Moraxella catarrhalis. According to recent comment (Nathwani
2005), the novel carbapenem ertapenem was the last agent
introduced that offered broad antimicrobial cover, but this drug is
not active against methicillin- or oxacillin-resistant Gram-positive
isolates and has limited activity against Pseudomonas species
and ESBL-producing Gram-negative bacteria.
The novel streptogramin combination of quinupristin/dalfopristin
has proven useful in patients with serious VRE infections and in
SSSIs, including those with MRSA (Kauffman 2003; Raghavan &
Linden 2004). However, the combination is not active against
infections caused by Ent. faecalis, and resistance has been
reported (Chow et al. 1997; Dowzicky et al. 2000).
Quinupristin/dalfopristin also has to be given via a central
intravenous catheter to avoid phlebitis, and can cause painful
arthralgia and myalgia (Kauffman 2003).
The glycopeptides vancomycin and teicoplanin (the latter is not
available in the USA) have featured prominently in the
management of multiresistant Gram-positive infection in the
past, but around 20% of enterococci in the USA are now
resistant to vancomycin (Abbanat et al. 2003). Moreover,
vancomycin is ototoxic and nephrotoxic (BNF 2005). These
considerations, and the threat of global acquisition of resistance
to glycopeptides by MRSA, have led to the development of
newer derivatives. These include ramoplanin, dalbavancin, and
telavancin, all of which show promise and are in clinical
development (Shah 2005; Bosso 2004).
There is therefore a need for research to discover and develop
agents with activity against a range of both Gram-positive and
Gram-negative pathogens, and against atypical pathogens,
particularly those most frequently associated with institutional,
resistant, or complicated infections. Moreover, research should be
ongoing and aimed at the development of “pipelines” of new
drugs, as resistance patterns are continually changing over time.
Clinical evidence with tigecycline
Antimicrobial activity
Tigecycline is active against most Gram-positive and Gram-
negative aerobes in addition to anaerobes and atypical organisms.
In preclinical studies, the drug was shown to have activity against
a broad range of Gram-positive pathogens including MRSA,
vancomycin-resistant  Ent. faecalis and Ent. faecium, and
penicillin-resistant  Str. pneumoniae; against Gram-negative
organisms such as ESBL-producing E. coli and Klebsiella
pneumoniae; and anaerobes such as the Bacteroides fragilis
group, and atypical organisms including Mycoplasma spp.,
Chlamydia spp., and rapidly growing mycobacteria (Edlund & Nord
2000; Goldstein et al. 2000; Roblin & Hammerschlag 2000; Kenny
& Cartwright 2001; Wallace et al. 2002; Jacobus et al. 2004).
Tigecycline has also been shown in animal models to be active
against a range of glycopeptide- and tetracycline-susceptible and
-resistant enterococci (Lefort et al. 2003; Nannini et al. 2003), and
the drug’s antistaphylococcal activity has been confirmed against
MRSA, being comparable to vancomycin and quinupristin/
dalfopristin, and superior to linezolid, imipenem, and beta-lactam
antimicrobials (Johnson et al. 2003). Other recent data confirm
antistaphylococcal activity against strains resistant to tetracycline,
minocycline, erythromycin, clindamycin, gentamicin, levofloxacin,
or rifampicin (Picazo et al. 2003), and against tetracycline- and
minocycline-resistant bacteremia isolates (Reynolds & Potz 2003).
The activity of tigecycline in clinical isolates was summarized on the
basis of minimum inhibitory concentration (MIC) breakpoints of
≤2 mg/L and ≥8 mg/L for susceptibility and resistance, respectively
(Garrison et al. 2005), but inconsistencies have been noted between
MIC limits obtained in different studies during the establishment of
quality control ranges for tigecycline. Because of this, further
investigations have been carried out, and have identified
discrepancies between results obtained in fresh Mueller–Hinton
broth (MHB) and those in aged medium that have been attributed to
acceleration of oxidative inactivation of tigecycline in the latter
(Bradford et al. 2005a; Petersen & Bradford 2005). As a result, the
Clinical Laboratory Standards Institute has approved quality control
ranges for tigecycline tested with fresh MHB, and this is now
considered the reference method for MIC testing of the drug
(Clinical and Laboratory Standards Institute 2005).
These standards have been applied to in-vitro susceptibility
testing of tigecycline with isolates from patients participating in
phase III studies assessing the clinical efficacy of the drug in
complicated SSSIs and intraabdominal infections (Bradford et al.
2005b). The results, which are summarized in Table 5, show a
similar pattern to that seen in preclinical studies. Tigecycline was
active (MIC ≤2 mg/L in most cases) against the most prevalent
pathogens in these patients, which included both Gram-positive
and Gram-negative strains of aerobic and anaerobic bacteria.
Staphylococci were inhibited regardless of their susceptibility or
otherwise to methicillin or oxacillin, and all enterococci were
inhibited by tigecycline at a concentration of 0.5 mg/L or less.
Good activity was also observed against beta-hemolytic
streptococci, whereas MICs for 90% of isolates (MIC90) for
tetracycline and minocycline were above resistance breakpoints.
Activity against Gram-negative pathogens, particularly the
Enterobacteriaceae, was also good (Table 5). All strains of
Citrobacter freundii were inhibited (MIC ≤2 mg/L), in contrast to
minocycline, tetracycline, aztreonam, and ceftazidime, MIC90
values for all of which were above resistance breakpoints. All
isolates of E. coli were inhibited by tigecycline at concentrations of
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Organism and no. of isolates (skin and skin structure Skin and skin structure infections Intraabdominal infections
infections; intraabdominal infections)
MIC50 (mg/L) MIC90 (mg/L) MIC50 (mg/L) MIC90 (mg/L)
Gram-positive
Staphylococcus aureus: methicillin-resistant (127; 16) 0.12 0.25 0.25 0.25
Staphylococcus aureus: methicillin-susceptible (373; 61) 0.12 0.25 0.12 0.25
Staphylococcus capitis (11; 7) 0.12 0.25 NA NA
Staphylococcus epidermidis: methicillin-resistant (44; 30) 0.12 0.5 0.25 0.5
Staphylococcus epidermidis: methicillin-susceptible (36; 40) 0.12 0.25 0.12 0.25
Staphylococcus haemolyticus (26; 18) 0.25 1 0.25 0.5
Staphylococcus hominis (16; 19) 0.12 0.12 0.12 0.25
Staphylococcus warneri (10; 7) 0.12 0.25 NA NA
Enterococcus avium (0; 57) NA NA 0.12 0.12
Enterococcus faecalis: vancomycin-susceptible (59; 109) 0.12 0.25 0.12 0.25
Enterococcus faecium: vancomycin-susceptible (11; 50) 0.06 0.12 0.06 0.12
Enterococcus hirae (3; 12) NA NA 0.06 0.06
Streptococcus pyogenes (84; 2) 0.06 0.12 NA NA
Streptococcus agalactiae (32; 5) 0.06 0.25 NA NA
Streptococcus dysgalactiae (14; 3) 0.12 0.25 NA NA
Streptococcus anginosus (29; 154) 0.06 0.12 0.06 0.12
Streptococcus constellatus (2; 61) NA NA 0.06 0.06
Streptococcus equisimilis (11; 0) 0.12 0.5 NA NA
Streptococcus intemedius (2; 10) NA NA 0.06 0.12
Streptococcus mitis (6; 16) NA NA 0.06 0.12
Streptococcus oralis (11; 37) 0.06 0.12 0.06 0.12
Streptococcus salivarius (2; 20) NA NA 0.06 0.12
Gram-negative
Citrobacter braakii (0; 15) NA NA 0.5 0.5
Citrobacter freundii (2; 29) NA NA 0.5 1
Enterobacter cloacae (41; 41) 0.5 1 1 1
Escherichia coli (90; 964) 0.25 0.5 0.25 0.5
Klebsiella oxytoca (18; 52) 0.25 0.5 0.5 0.5
Klebsiella pneumoniae (32; 152) 0.5 1 0.5 1
Morganella morganii (3; 19) NA NA 2 2
Proteus mirabilis (39; 46) 4 4 2 4
Proteus vulgaris (2; 10) NA NA 1 2
Serratia marcescens (10; 12) 1 2 2 4
Acinetobacter calcoaceticus/baumanii complex (16; 16) 0.25 1 0.5 2
Pseudomona aeruginosa (32; 126) 16 32 16 32
Comamonas testosterone (0; 10) NA NA 0.06 0.12
Anaerobes
Bacteroides fragilis (24; 244) 0.12 0.25 0.5 4
Bacteroides caccae (2; 19) NA NA 0.25 8
Bacteroides distasonis (0; 23) NA NA 2 2
Bacteroides ovatus (0; 21) NA NA 0.25 4
Bacteroides thetaiomicron (3; 108) NA NA 0.5 2
Bacteroides uniformis (4; 53) NA NA 0.25 1
Bacteroides vulgatus (0; 33) NA NA 0.25 2
Clostridium innocuum (1; 12) NA NA ≤0.06 ≤0.06
Clostridium perfringens (5; 51) NA NA 0.12 1
Eubacterium lentum (0; 14) NA NA 0.12 0.5
Propionibacterium acnes (6; 17) NA NA ≤0.06 0.12
Peptostreptococcus micros (1; 39) NA NA ≤0.06 ≤0.06
Fusobacterium nucleatum (4; 11) NA NA 0.12 0.12
Veillonella spp. (0; 12) NA NA 0.25 0.5
MIC50, minimum inhibitory concentration for 50% of isolates; MIC90, minimum inhibitory concentration for 90% of isolates; NA, not applicable.
Table 5 | In-vitro susceptibility data for tigecycline. Activity against isolates from phase III clinical studies in patients with skin and
skin structure infections or intraabdominal infections (Bradford et el. 2005b)2 mg/L or less, and good activity was noted against K. pneumoniae
isolates (including those that showed resistant to ceftazidime and
aztreonam) and K. oxytoca. MICs ranged from 0.5 to 8 mg/L for
Serratia marcescens, but lower values for most strains were
reflected by the MIC50 values reported of 1 or 2 mg/L. There was a
trend towards higher MICs for the Proteeae than for other
Enterobacteriaceae. For strains from patients with intraabdominal
infections, MIC90 was 2 mg/L for Morganella morganii and Proteus
vulgaris. Tigecycline was also active against Acinetobacter
baumanii, but was less active against Ps. aeruginosa (Table 5).
Tigecycline was also active against anaerobic pathogens, and all
Gram-positive anaerobes were inhibited by tigecycline 2 mg/L or
less. There was a wide range of MICs against members of the
B. fragilis group (0.06–16 mg/L), but MIC50 values for all species
of Bacteroides were 2 mg/L or less.
Clinical cure and microbiologic eradication in patients
Clinical studies of tigecycline have focused to date on clinical
cure and microbiologic eradication in patients with complicated
SSSIs or intraabdominal infections. The primary endpoint of
choice in such trials should be cure and eradication at a
predefined test-of-cure visit that postdates the end of treatment.
Cures that are apparent when treatment ceases may later
relapse, with subsequent requirement for further therapy. Clinical
evidence for the efficacy of tigecycline against the serious and
complicated infection types examined to date appears good, and
overall clinical activity is as might be expected on the basis of the
drug’s in-vitro bacteriologic profile.
In all studies reviewed, except for one phase II trial in which two
dosages were compared, tigecycline was given intravenously as a
100 mg loading dose followed by 50 mg every 12 hours for at least
5 days (Table 6). Two large, randomized, multicenter, double-blind
phase III studies (level 2 evidence) have recently compared
tigecycline with intravenous combination therapy with vancomycin
1 g and aztreonam 2 g every 12 hours for up to 14 days in
1057 patients [clinically modified intent-to-treat (ITT) populations]
with complicated SSSIs (Breedt et al. 2005; Sacchidanand et al.
2005). Both studies showed no significant differences between
either regimen in terms of clinical cure or microbiologic eradication
rates (see also Table 6). Clinical cure rates (where treatment was
observed to resolve the infection process) were measured in the
clinically modified ITT populations (patients who received at least
one dose of study drug and who showed clinical signs of a
complicated SSSI) and microbiologic eradication in the
microbiologically evaluable populations. Patients were deemed to
be microbiologically evaluable if they satisfied all protocol
requirements and had a baseline culture containing at least one
causative isolate that was susceptible to both study treatments.
Across the difference treatments in both studies, clinical cure rates
ranged from 75.5 to 86.9% (Table 6).
Level 2 evidence is also available from two randomized, double-
blind, and multicenter studies comparing tigecycline with
imipenem/cilastatin (500 mg/500 mg every 6 hours intravenously,
weight-adjusted where necessary) for 5 to 14 days for
complicated intraabdominal infections (Fomin et al. 2005; Oliva et
al. 2005). Of 825 (Oliva et al. 2005) and 817 (Fomin et al. 2005)
patients in the modified ITT populations who received more than
one dose of study medication, 621 and 641, respectively, were
included in the microbiologically modified ITT populations of
patients who had clinical evidence of an intraabdominal infection,
met minimal disease criteria, and who had a confirmed baseline
isolate. Of these, 502 (Oliva et al. 2005) and 523 (Fomin et al.
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Level of Outcomes Comparators Study population Reference
evidence
2 CC in 84.3% (TIG) and 86.9% (VAN/AZT) of patients TIG 50 mg q 12 h vs  Clinically modified ITT population Breedt et al. 
(clinically modified ITT population). ME in 84.8% VAN 1 g + AZT 2 g q 12 h of 520 with complicated skin and 2005
and 93.2% for microbiologically evaluable population skin structure infections
of 312 (criteria for noninferiority of TIG met)
2 CC in 75.5% (TIG) and 76.9% (VAN/AZT) of patients TIG 50 mg q 12 h vs  Clinically modified ITT population  Sacchidanand 
(clinically modified ITT population). ME in 80.9% VAN 1 g + AZT 2 g q 12 h of 537 with complicated skin and  et al. 2005
and 77.9% for microbiologically evaluable population skin structure infections
of 228 (criteria for noninferiority of TIG met)
2 CC in 73.5% (TIG) and 78.2% (IMI/CIL). ME in 80.6% TIG 50 mg q 12 h vs IMI/CIL Microbiologically modified ITT  Oliva et al. 
and 82.4% for microbiologically evaluable population 500 mg/500 mg q 6 h population of 621 patients with 2005
of 502 (criteria for noninferiority of TIG met) complicated intraabdominal infections
2 CC in 86.6% (TIG) and 84.6% (IMI/CIL). ME in 91.3% TIG 50 mg q 12 h vs IMI/CIL Microbiologically modified ITT  Fomin et al. 
and 89.9% for microbiologically evaluable population 500 mg/500 mg q 6 h population of 641 patients with 2005
of 523 (criteria for noninferiority of TIG met) complicated intraabdominal infections
3 CC in 67% (TIG 25 mg) and 74% (TIG 50 mg) of TIG 25 mg q 12 h vs  160 with complicated skin and  Postier et al. 
patients. ME in 56% and 69% TIG 50 mg q 12 h skin structure infections 2004
3 CC in 55% of patients TIG 50 mg q 12 h 111 with complicated intraabdominal  Murray et al.
infections 2003
5 Full recovery with TIG (n=2); no response with TIG (dosage not stated) 7 ventilator-assisted patients with resistant Wilson 2004
colistin (n=5) Acinetobacter baumanii pneumonia
AZT, aztreonam; CC, clinical cure; IMI/CIL, imipenem/cilastatin; ITT, intent-to-treat; ME, microbiologic eradication; q 6 h, every 6 hours; q 12 h, every 12 hours; TIG, tigecycline; VAN,
vancomycin.
Table 6 | Summary of outcomes evidence for tigecycline: clinical and microbiologic cure in patients with complicated skin and skin
structure or intraabdominal infections189
2005) were microbiologically evaluable. The mean duration of
therapy across both studies was approximately 8 days. At the
test-of-cure assessment (12–44 days after therapy), clinical cure
rates were 73.5 (Oliva et al. 2005) and 86.6% (Fomin et al. 2005)
for tigecycline, and 78.2 (Oliva et al. 2005) and 84.6% (Fomin et
al. 2005) for imipenem/cilastatin (Table 6). At approximately 80
(Oliva et al. 2005) and 90% (Fomin et al. 2005), rates of
microbiologic eradication were also similar between treatments in
both studies for microbiologically evaluable populations.
Tigecycline met statistical criteria for noninferiority to
imipenem/cilastatin for all endpoints in both studies.
The most common diagnosis in both studies was complicated
appendicitis (around half of all patients overall), followed by
perforated intestine and gastric or duodenal ulcer (Oliva et al.
2005), or by cholecystitis or intraabdominal abscess (Fomin et al.
2005). E. coli was the most commonly isolated aerobe, followed
by Klebsiella spp., in both trials. Oliva et al. (2005) reported
identification of six ESBL-producing E. coli and seven ESBL-
producing K. pneumoniae isolates before therapy in their study.
Postier et al. (2004) have reported fully their phase II study (level
3 evidence) in 160 ITT patients with complicated SSSIs who
received tigecycline 25 mg (n=79) or 50 mg (n=81) every 12 hours
for 7–14 days. The primary endpoint in this well-designed and
executed study was clinically observed cure (defined as
resolution or improvement of all signs and symptoms to the extent
that no further antibiotic therapy was necessary) at the test-of-
cure visit approximately 3 weeks after the start of therapy.
Bacteriologic responses were assessed according to the National
Committee for Clinical Laboratory Standards (NCCLS; now
known as the Clinical Laboratory Standards Institute) criteria and
clearly defined MIC breakpoints; pharmacokinetic and safety
analyses were also included. The main diagnoses were ulcer with
acute infection (35% of patients) and major abscess (31%). Of all
patients, 82% were infected with at least one of the pathogens
selected for bacteriologic analysis: methicillin-resistant or
-sensitive Staph. aureus, Str. pyogenes, E. coli, Ent. faecalis, or
Ent. faecium. As shown in Table 6, clinical cure as specified was
noted in 67 and 74% of patients in the 25 mg and 50 mg groups,
respectively, at the test-of-cure visit (six patients in each group
required further treatment between the end-of-treatment and test-
of-cure visits). In the 25 mg group, 56% of patients had
microbiologic eradication, which was compared with 69% in the
50 mg group. The MICs required for 90% of all selected isolates
ranged from 0.06 to 0.5 mg/L (Postier et al. 2004).
Tigecycline was also effective in patients with complicated
intraabdominal infections (mostly perforated or gangrenous
appendicitis, complicated cholecystitis, perforated diverticulitis,
or peritonitis) in a noncomparative phase II study (Murray et al.
2003). In this trial, presented as an abstract and summarized in
Table 6, 111 ITT patients received tigecycline for up to 14 days,
after which 55% were assessed as clinically cured at the test-of-
cure visit. These patients represented a challenging population,
meeting inclusion criteria that included a need for surgical
extirpation of the source of infection plus antibiotic therapy, and
subsequent isolation of both aerobic and anaerobic cultures.
Although not considered strong evidence, a small descriptive
study (level 5 evidence) in a series of seven patients requiring
intensive care in a UK district general hospital has indicated that
tigecycline is likely to be useful in persons with ventilator-
assisted pneumonia associated with resistant Acinetobacter
infection (Table 6) (Wilson 2004). Tigecycline was tried
successfully in two patients in this unit after increasing problems
with resistance to carbapenems, tobramycin, amikacin, colistin,
and minocycline, to the point where one patient had already
died with A. baumanii infection resistant to all available
antiinfective agents. The other five patients in this series were
treated with colistin and failed to respond, but it was not clear
from the abstract presented as to how these patients were
managed thereafter.
Tolerability and adverse events
Clinical results to date bear out preclinical findings with tigecycline
in healthy persons and those with renal disease that showed linear
pharmacokinetics and good tolerability of the drug with no need for
dosage adjustments because of age, gender, or renal impairment
(Troy et al. 2003; Meagher et al. 2004; Muralidharan et al. 2005a,b).
Nausea and vomiting appear to be the treatment-emergent adverse
events of chief concern, and affected 35% of patients who received
tigecycline 50 mg every 12 hours in the phase II study of Postier et
al. (2004). Of the five treatment withdrawals, two were associated
with nausea and vomiting and one with rash; none of these events
were life threatening. Laboratory abnormalities (elevated hepatic
enzymes, raised blood urea nitrogen levels, or anemia) considered
likely to be associated with tigecycline therapy were also noted in
nine patients, but none led to treatment discontinuation. Overall,
nausea and vomiting were cited as the most common events with
tigecycline in all other studies. Rates were higher than with
vancomycin/aztreonam in patients with complicated SSSIs in
phase III trials (Breedt et al. 2005; Sacchadinand et al. 2005),
although vancomycin/aztreonam was associated with higher rates
of hepatic enzyme elevation, pruritus, and rash (Table 7). In one
phase III study in patients with intraabdominal infections, the
increases in rates of nausea and vomiting with tigecycline over
imipenem/cilastatin approached or attained statistical significance
(Table 7), but there were no statistically significant differences
between groups in this respect in the other phase III intraabdominal
infection trial (Fomin et al. 2005).
Ongoing studies
The studies reported so far indicate the likely utility of tigecycline
in complicated and/or nosocomial infections of particular interest
at the present time, but trials are also in progress to examine the
activity of the drug in other serious and problematic infections.
These include:
• an open-label and noncomparative trial in patients with serious
resistant Gram-negative infections (e.g. A. baumanii,
Enterobacter spp., K. pneumoniae, etc.) (evidence level 3)
• randomized and double-blind comparisons with levofloxacin in
patients with community-acquired pneumonia (evidence level 2)
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serious infections in patients with VRE, and with vancomycin
for serious infections in patients with MRSA. Conditions
covered include bacteremia, pneumonia, and bacterial SSSIs
(evidence level 2)
• a randomized and double-blind comparison with imipenem/
cilastatin in patients with nosocomial pneumonia (evidence
level 2).
Completion of these large-scale studies will provide a more
complete picture of the overall activity of tigecycline in patients
with infections associated with major management problems at
the present time, and results are therefore awaited.
Economic evidence
Early level 3 evidence, presented as an abstract, suggests that
reduction of length of hospital stay may accrue from the use of
tigecycline in patients with complicated SSSIs (Table 8). Pooling
of data from two randomized, double-blind, international studies
(Breedt et al. 2005; Sacchidanand et al. 2005) in a modified ITT
population of 1116 patients with complicated SSSIs showed no
difference in length of hospital stay between patients receiving
tigecycline and those receiving vancomycin/aztreonam (Mallick &
Solomon 2005). However, when risk factors for significantly
longer stay (diabetes, trauma, Gram-negative infection, absence
of cure, use of concomitant medication, infected ulcer, need for
intensive care, and non-US hospital setting) were identified and
adjusted for, tigecycline therapy was associated with a significant
1-day reduction in length of hospital stay. This difference was
almost entirely attributable to the subgroup of patients with
Gram-negative infections (18%, mostly E. coli). Among 186
clinical intent-to-treat patients treated in US centers and with
complete hospitalization data (Mallick et al. 2005), tigecycline
was associated with a reduction in length of hospital stay of
1.6 days (P=0.04) after adjusting for identified risk factors that
included prior surgery (+2.9 days; P=0.036) and initiation of
intravenous antibiotic treatment in the intensive care unit
(+10.8 days; P=0.0008).
Yu et al. (2005) have reported a nonsignificant trend towards
reduced duration of treatment relative to vancomycin/aztreonam
when patients with complicated SSSIs were treated with
tigecycline (Table 8). This analysis was based retrospectively on
the same two clinical studies as above (Breedt et al. 2005;
Sacchidanand et al. 2005), and included 1041 patients from the
modified ITT population with complete hospitalization data.
Independent risk factors for prolonged hospitalization that were
identified and adjusted for were diabetes, infected ulcer, female
gender, and concomitant use of antibiotics. It should be noted
here that length of stay and duration of treatment were only two
of several measured health outcomes, and that their reduction
were not prospectively defined in the protocols of the two clinical
trials on which these economic analyses were based.
Resource utilization
Apart from the preliminary level 3 evidence described in the
previous section, there are as yet no other published economic
data relating to the use of tigecycline at this stage in the drug’s
development, but results indicate the potential of novel
antiinfectives such as tigecycline in complicated, nosocomial,
and/or resistant infections. The pace at which resistance to
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Level of Outcomes Comparators Study population Reference
evidence
2 Similar rates of TEAEs in both groups. More (P<0.05) TIG 50 mg q 12 h vs VAN Safety population of 543 with complicated  Breedt et al. 
nausea (25.2 vs 5.2%) and vomiting (12 vs 2.2%) 1 g + AZT 2 g q 12 h skin and skin structure infections 2005
with TIG; more increased AST (5.2 vs 1.5%) or ALT
(6.7 vs 1.8%) with VAN/AZT
2 Similar rates of TEAEs in both groups. More (P<0.05) TIG 50 mg q 12 h vs VAN  Safety population of 573 patients with  Sacchadinand 
nausea (43.2 vs 11%), vomiting (26.7 vs 5%), 1 g + AZT 2 g q 12 h complicated skin and skin structure  et al. 2005
dyspepsia (5.5 vs 1.8%), and anorexia (4.1 vs 0.7%) infections
with TIG; more abnormal LFTs (5.7 vs 1%), pruritus
(10.7 vs 4.5%), and rash (7.8 vs 2.7%) with VAN/AZT
2 Most common TEAEs: nausea (31% TIG and 24.8% TIG 50 mg q 12 h vs IMI/CIL Modified ITT cohort of 825 patients with  Oliva et al. 
IMI/CIL; P=0.052) and vomiting (25.7% TIG and 19.4% 500 mg/500 mg q 6 h complicated intraabdominal infections 2005
IMI/CIL; P=0.037)
2 Most common TEAEs: nausea (17.6% TIG and 13.3% TIG 50 mg q 12 h vs IMI/CIL  Modified ITT cohort of 817 patients with  Fomin et al. 
IMI/CIL; P=0.1) and vomiting (12.6% TIG and  500 mg/500 mg q 6 h complicated intraabdominal infections 2005
9.2% IMI/CIL; P=0.144)
3 Commonest TEAEs: nausea (22% with 25 mg; 35% TIG 25 mg q 12 h vs TIG  160 with complicated skin and skin  Postier et al. 
with 50 mg). 5 discontinuations with 50 mg. 50 mg q 12 h structure infections  2004
No life-threatening reactions
3 Nausea and vomiting most common TEAEs TIG 50 mg q 12 h 111 with complicated intraabdominal  Murray et al. 
infections 2003
5 No adverse events with TIG therapy TIG (dosage not stated) 7 ventilator-assisted patients with resistant  Wilson 2004
Acinetobacter baumanii pneumonia; 2 received 
TIG, 5 received colistin
ALT, alanine aminotransferase; AST, aspartate aminotransferase; AZT, aztreonam; IMI/CIL, imipenem/cilastatin; ITT, intent-to-treat; LFT, liver function test; q 6 h, every 6 hours; q 12 h, every
12 hours; TEAE, treatment-emergent adverse event; TIG, tigecycline; VAN, vancomycin.
Table 7 | Summary of outcomes evidence for tigecycline: adverse events
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antimicrobial therapy develops continues to increase, but the
magnitude of the effect of this resistance on outcomes and
consumption of healthcare resources remains poorly understood.
A review of this subject by Cosgrove and Carmeli (2003) has
attempted to address these issues. Resistance often leads to a
mismatch between empiric treatment and susceptibility, and thus
to a significant delay in the delivery of effective antimicrobial
therapy. Such delay resulted in significantly extended duration of
hospitalization and increased hospital charges for patients with
ESBL-producing strains of K. pneumoniae or E. coli relative to
controls in one study (Lautenbach et al. 2001). Resistant
organisms may also require treatment with more toxic or
aggressive therapy than might usually be considered: colistin for
resistant Pseudomonas or Acinetobacter strains may cause renal
dysfunction (Levine et al. 1991), and total resistance may lead to
the need for surgery, with high rates of mortality being seen in
patients whose locus of infection cannot be surgically removed
(Harris et al. 1999).
From the hospital perspective, most available studies have shown
a link between antibiotic resistance and increased mortality,
morbidity, and cost (Cosgrove & Carmeli 2003). These results,
however, are limited because they do not include costs
associated with care in the community and in rehabilitation
facilities other than hospitals. The long-term effects of a resistant
infection on future health, and on loss of work and family time
caused by prolonged hospitalization or incapacity, are also
difficult to estimate. The US Congress Office of Technology
Assessment (1995) estimated the national cost of antibiotic
resistance in that country to be $US4 billion for the year 1995, but
this conservative assessment included only direct patient effects
without wider societal costs.
The chief value of antiinfective drugs introduced at the present
time for the types of infection under discussion lies in their
potential in empiric therapy. Any agent that can be given with a
good chance of success early in the course of disease will
contribute to the avoidance of much morbidity and need for
additional therapy following on from treatment failure as
described above. Clinical results show that tigecycline is likely to
fall into this category, but reliable outcomes and economic data
pertaining to the use of the drug will have to be assessed in direct
comparisons with other therapies in specified institutions, as
treatment and resistance patterns vary between locations within
and between countries. The cost to providers of drugs used in
any study will also have to be known for reliable comparisons to
be made, as acquisition costs for novel broad-spectrum
antibiotics are typically much higher than those of established
agents. Nevertheless, the activity of tigecycline in preclinical
and clinical studies to date suggest that the drug does indeed
have the potential to circumvent adverse outcomes and
subsequent costs resulting from treatment failure in complicated
and resistant infections.
Patient group/population
Current product registration in the USA limits the use of
tigecycline to adults with intraabdominal and complicated SSSIs,
but the range of clinical trials still underway indicates that the drug
is expected to contribute to the treatment of patients with a much
wider range of conditions caused by multiresistant pathogens.
Chief among these are likely to be patients with pneumonia (both
hospital- and community-acquired), including some with atypical
infections, patients with bacteremia/sepsis, and those with Gram-
negative infections. Patients in the last group may benefit in
particular, as tigecycline has good activity against a number of
Gram-negative pathogens that are resistant to other novel
antibacterials, most of which are directed against Gram-positive
infections (Abbanat et al. 2003; Nathwani 2005). There is no oral
formulation of tigecycline, and the drug must be given
intravenously, but this consideration is of little consequence in
light of the characteristics of the target patient group, the large
majority of whom will have undergone surgery or will be
sufficiently unwell to require care in hospital or some other
institutional setting.
Preliminary level 5 evidence indicates that tigecycline is also likely
to be useful in high-risk patients in intensive care who are
particularly vulnerable to multiresistant pathogens (Wilson 2004).
Ethical considerations make the conduct of randomized trials in
patients of this type more difficult than in other groups, but
accumulating clinical experience with tigecycline is likely to shed
more light on the utility of the drug in this setting.
The use of tigecycline is likely to be empiric in the first instance in
many patients, as early treatment is important in the management
of serious infections. The broad spectrum of activity, which
includes Gram-negative pathogens and some atypical organisms,
suggests that this empiric therapy will be continued and should
be successful in most patients after identification of the infective
Level of Outcomes Comparators Study population Reference 
evidence
2 Trend towards shorter treatment duration (P=0.072) TIG 50 mg q 12 h vs VAN  1041 with complicated skin and skin  Yu et al. 2005
with TIG after adjustment for risk factors 1 g + AZT 2 g q 12 h structure infections and with complete 
hospitalization data
3 Faster discharge (–1 day; hazard ratio 1.22; P=0.019) TIG 50 mg q 12 h vs VAN  1116 with complicated skin and skin  Mallick & 
with TIG after adjustment for risk factors. Discharge 1 g + AZT 2 g q 12 h structure infections Solomon 2005; 
time reduced by 1.6 days (P=0.04) when restricted to Mallick et al. 
186 patients from US centers and with complete data 2005
AZT, aztreonam; q 12 h, every 12 hours; TIG, tigecycline; VAN, vancomycin.
Table 8 | Summary of economic outcomes for tigecycline
 agent. This situation could change, however, if resistance were to
emerge, and it will therefore be important to combine appropriate
use of tigecycline with effective infection control measures and
close monitoring of susceptibility patterns.
Tigecycline has been approved in the USA, Mexico, Venezuela,
and Brazil for the treatment of complicated intraabdominal
infections and complicated skin and skin structure infections in
adults (Anon. 2005). It is likely that these indications will be
expanded as the results of ongoing phase III studies are released
(filings are expected for hospital- and community-acquired
pneumonia in September 2006). Registration is awaited in
Australia, Canada, the European Union, and Switzerland. The use
of tigecycline in children has not yet been evaluated.
Outcomes summary
Tigecycline has recently been introduced into clinical practice as
part of the effort to combat the growing problem of bacterial
resistance to antiinfective therapy, particularly in patients with
serious or complicated infections and those in hospitals and other
institutions. Early reports of the first of the large-scale randomized
clinical trials to be conducted have led to the approval of tigecycline
for the treatment of complicated SSSIs and intraabdominal
infections in the USA, Mexico, Venezuela, and Brazil, with approvals
expected to follow in other countries, and other indications added,
as ongoing studies report. Published or impending trials focus on
comparisons of tigecycline with established agents that are already
in common use for serious infections. Substantial evidence so far
shows that tigecycline is as effective as these other agents, but
superiority has not been shown. As resistance patterns vary widely
between centers and countries, more research and clinical
experience will be necessary before a more complete picture begins
to emerge. Comparisons of tigecycline with other new agents
developed specifically for use against the modern generation of
multiresistant pathogens will also be needed. These will be of special
interest  because of tigecycline’s activity against Gram-negative and
some atypical pathogens.
The possibility of development of resistance to any new
antimicrobial is a significant source of concern. Tigecycline
appears to have the potential to resist common mechanisms of
resistance, as shown by unsuccessful attempts to create
tigecycline-resistant isolates in the laboratory by exposing
pathogens to suboptimal concentrations of the drug (Projan
2000). In addition, tigecycline is not affected by efflux, ribosomal
protection, DNA gyrase mutation, binding site modification, or
beta-lactamases (Bradford 2004).
Clinical endpoints being measured in trials are as expected for a
new antiinfective agent. The outcomes of clinical cure and
bacteriologic eradication have immediate clinical relevance and
show how well the drug works in the setting in which it is given.
However, the economic implications attached to the introduction
of tigecycline to clinical practice are less clear at present. For
economic benefits to be realized, tigecycline will have to maintain
high rates of clinical success against organisms resistant to other
drugs, with sustained efficacy as empiric therapy in cases where
other agents may fail. Longer term evaluation will be needed to
show how these factors translate into other (e.g. quality-of-life
and societal) benefits beyond the perspective of the institution
where treatment is administered. Limited evidence suggests that
the use of tigecycline may result in more rapid discharge of
patients from hospital back into the community; ultimately, this
will require confirmation with evidence from properly designed
economic studies. It would also be of value to determine any
effect of tigecycline on length of stay in intensive care. Tolerability
in clinical studies appears good, and similar to the beta-lactam
comparators used to date (imipenem/cilastatin and aztreonam are
associated chiefly with nausea, vomiting, and diarrhea).
Vancomycin may be ototoxic and hepatotoxic in some patients,
but tigecycline does not appear to be associated with potentially
serious effects such as organ toxicity.
The introduction of tigecycline is timely in an era of increasing
bacterial resistance and relative shortage of new antibacterial
agents. Current evidence shows that this novel glycylcycline is
effective in the patient population in which it is being targeted, but
it is not yet clear whether it is more effective or delivers better
outcomes than other agents of interest. Continuing evolution of
resistance patterns worldwide will no doubt affect the relative
placing of tigecycline and other antiinfectives (both old and new),
and further evidence will need to be gathered to show whether
overall benefits outweigh high acquisition costs (as with all novel
antibacterials) relative to older agents.
References
Abbanat D, Macielag M, Bush K. Novel antibacterial agents for the treatment of
serious Gram-positive infections. Expert Opin Investig Drugs. 2003;12:379–399.
Anon. Recommendations for preventing the spread of vancomycin resistance:
recommendations of the Hospital Infection Control Practices Advisory
Committee (HICPAC). Am J Infect Control. 1995;23:87–94.
Anon. Monitoring hospital-acquired infections to promote patient safety –
United States, 1990-1999. MMWR Morb Mortal Wkly Rep. 2000;49:149–153.
Anon. FDA approves superbug antibiotic, Tygacil (tigecycline). Medical News
Today. June 17, 2005. Available at: http://www.medicalnewstoday.com/
medicalnews.php?newsid=26293# (accessed June 24, 2005).
BNF (British National Formulary) 49; March, 2005. Available at:
http://www.bnf.org/bnf (accessed July 6, 2005).
Bosso JA. The impact of antibiotic management on resistance.
Pharmacotherapy. 2004;24:224S–231S.
Bradford PA. Tigecycline: a novel first in class glycylcycline. Clin Microbiol
Newslett. 2004;26:163–168.
Bradford PA, Petersen PJ, Young M, Jones CH, Tischler M, O’Connell J.
Tigecycline MIC testing by broth dilution requires use of fresh medium or
addition of the biocatalytic oxygen-reducing agent oxyrase to standardize the
test method. Antimicrob Agents Chemother. 2005a;49:3903–3909.
Bradford PA, Weaver-Sands T, Petersen PJ. In vitro activity of tigecycline
against isolates from patients enrolled in phase 3 clinical trials of treatment for
complicated skin and skin-structure infections and complicated intra-abdominal
infections. Clin Infect Dis. 2005b;41:S315–S332.
Breedt J, Teras J, Gardovskis J, et al. Safety and efficacy of tigecycline in
treatment of skin and skin structure infections: results of a double-blind phase
3 comparison study with vancomycin-aztreonam. Antimicrob Agents
Chemother. 2005;49:4658–4666.
Chopra I. Glycylcyclines: third-generation tetracycline antibiotics. Curr Opin
Pharmacol. 2001;1:464–469.
Tigecycline | outcomes review
© 2006 Core Medical Publishing Limited 192193
Chow JW, Donahedian SM, Zervos MJ. Emergence of increased resistance to
quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia.
Clin Infect Dis. 1997;24:90–91.
Clinical and Laboratory Standards Institute. Performance standards for antimicrobial
susceptibility testing – fifteenth informational supplement. Wayne, PA: Clinical and
Laboratory Standards Institute; 2005. CLSI document number M100-S15.
Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and
economic outcomes. Clin Infect Dis. 2003;36:1433–1437.
Crowcroft NS, Catchpole M. Mortality from methicillin-resistant Staphylococcus
aureus in England and Wales: analysis of death certificates. BMJ.
2002;325:1390–1391.
Diekema DJ, BootsMiller BJ, Vaughn TE, et al. Antimicrobial resistance trends and
outbreak frequency in United States hospitals. Clin Infect Dis. 2004;38:78–85.
Dowzicky M, Talbot GH, Feger C, Prokocimer P, Etienne J, Leclerq R.
Characterization of isolates associated with emerging resistance to
quinupristin/dalfopristin (Synercid) during a worldwide clinical program. Diagn
Microbiol Infect Dis. 2000;37:57–62.
Edlund C, Nord CE. In-vitro susceptibility of anaerobic bacteria to GAR-936,
a new glycylcycline. Clin Microbiol Infect. 2000;6:159–163.
Fomin P, Beuran M, Gradauskas A, et al; 306 Study Group. Tigecycline is
efficacious in the treatment of complicated intra-abdominal infections. Int J
Surg. 2005;3:35–47.
Garrison MW, Neumiller JJ, Setter SM. Tigecycline: an investigational
glycylcycline antimicrobial with activity against resistant Gram-positive
organisms. Clin Ther. 2005;27:12–22.
Goldstein EJC, Citron DM, Merriam CV, Warren Y, Tyrrell K. Comparative in vitro
activities of GAR-396 against aerobic and anaerobic animal and human bite
wound pathogens. Antimicrob Agents Chemother. 2000;44:2747–2751.
Gravestock MB. Recent developments in the discovery of novel oxazolidinone
antibacterials. Curr Opin Drug Discov Devel. 2005;8:469–477.
Guay DR. Oritavancin and tigecycline: investigational antimicrobials for
multidrug-resistant bacteria. Pharmacotherapy. 2004;24:58–68.
Halle E, Padberg J, Rosseau S, Klare I, Werner G, Witte W. Linezolid-resistant
Enterococcus faecium and Enterococcus faecalis isolated from a septic patient:
report of first isolates in Germany. Infection. 2004;32:182–183.
Harris A, Torres-Viera C, Venkataraman L, DeGirolami P, Samore M, Carmeli Y.
Epidemiology and clinical outcomes of patients with multiresistant
Pseudomonas aeruginosa. Clin Infect Dis. 1999;28:1128–1133.
IDSA (Infectious Diseases Society of America). Bad bugs, no drugs. As
antibiotic discovery stagnates…a public health crisis brews. Available at:
http://www.idsociety.org/ (accessed June 24, 2005a).
IDSA (Infectious Diseases Society of America). Bad bugs, no drugs executive
summary. Antibiotic-resistant bacterial pathogens: why we are concerned?
Available at: http://www.idsociety.org/ (accessed June 24, 2005b).
Jacobus NV, McDermott LA, Ruthazer R, Snydman DR. In vitro activities of
tigecycline against the Bacteroides fragilis group. Antimicrob Agents
Chemother. 2004;48:1034–1036.
Johnson B, Stevens T, Bouchillon S, et al. Tigecycline (GAR-936) a novel
glycylcycline with promising anti-staphylococcal activity. Proceedings of the
43rd Annual Interscience Conference on Antimicrobial Agents and
Chemotherapy; September 14–17, 2003; Chicago, IL. Abstract E-1536.
Kauffman CA. Therapeutic and preventative options for the management of
vancomycin-resistant enterococcal infections. J Antimicrob Chemother.
2003;51(Suppl. S3):iii23–iii30.
Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis, M.
pneumoniae, and Ureaplasma urealyticum to GAR-396, dalfopristin,
dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-
dalfopristin, and telithromycin compared to their susceptibilities to reference
macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother.
2001;45:2604–2608.
Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-
spectrum beta-lactamase-producing Escherichia coli and Klebsiella
pneumoniae: risk factors for infection and impact of resistance on outcomes.
Clin Infect Dis. 2001;32:1162–1171.
Lefort A, Lafaurie M, Massias L, et al. Activity and diffusion of tigecycline (GAR-
936) in experimental enterococcal endocarditis. Antimicrob Agents Chemother.
2003;47:216–222.
Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or
vancomycin plus rifampicin in methicillin-resistant Staphylococcus aureus
endocarditis. Ann Intern Med. 1991;115:674–680.
Mallick R, Solomon S. The duration of hospitalization (length of stay) in patients
hospitalized with complicated skin and skin structure infections: identifying
clinical and microbiological risk factors in a comparison of tigecycline with
vancomycin/aztreonam. 15th European Congress of Clinical Microbiology and
Infectious Diseases; May 1–4, 2005; Prague, Czech Republic. Abstract P1181.
Mallick R, Yu H, Weber DJ. Length of stay in patients hospitalized in the United
States with complicated skin and skin structure infections (cSSSI): Findings
from pooled clinical studies comparing tigecycline and vancomycin/aztreonam.
Infectious Disease Society of America, 43rd Annual Meeting; October 6–9,
2005; San Francisco, CA. Abstract 367.
Mangili A, Bica I, Snydman DR, Hamer DH. Daptomycin-resistant, methicillin-
resistant Staphylococcus aureus bacteremia. Clin Infect Dis.
2005;40:1058–1060.
Meagher A, Cirincione B, Piedmonte M, Troy S, Ambrose PG. Pharmacokinetics
of tigecycline in healthy adult volunteers and in subjects with renal impairment.
14th European Congress of Clinical Microbiology and Infectious Diseases; May
1–4, 2004; Prague, Czech Republic. Abstract P1023.
Meka VG, Pillai SK, Sakoulas G, et al. Linezolid resistance in sequential
Staphylococcus aureus isolates associated with a T2500A mutation in the 23S
rRNA gene and loss of a single copy of rRNA. J Infect Dis. 2004;190:311–317.
Muralidharan G, Fruncillo RJ, Micalizzi M, Raible DG, Troy SM. Effects of age
and sex on single-dose pharmacokinetics of tigecycline in healthy subjects.
Antimicrob Agents Chemother. 2005a;49:1656–1659. 
Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of
tigecycline after single and multiple doses in healthy subjects. Antimicrob
Agents Chemother. 2005b;49:220–229.
Murray J, Wilson S, Klein S, Yellin A, Loh E. The clinical response to tigecycline
in the treatment of complicated intra-abdominal infections in hospitalized
patients, a phase 2 clinical trial. Proceedings of the 43rd Annual Interscience
Conference on Antimicrobial Agents and Chemotherapy; September 14–17,
2003; Chicago, IL. Abstract L-739.
Mutnick AH, Enne V, Jones RN. Linezolid resistance since 2001: SENTRY
Antimicrobial Surveillance Program. Ann Pharmacother. 2003;37:769–774.
Nannini EC, Pai SR, Singh KV, Murray BE. Activity of tigecycline (GAR-936), a
novel glycyclcycline, against enterococci in the mouse peritonitis model.
Antimicrob Agents Chemother. 2003;47:529–532.
Nathwani D. Tigecycline: clinical evidence and formulary positioning. Int J
Antimicrob Agents. 2005;25:185–192.
Oliva ME, Rekha A, Yellin A, et al; 301 Study Group. A multicenter trial of the
efficacy and safety of tigecycline versus imipenem/cilastatin in patients with
complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW;
ClinicalTrials.gov Identifier: NCT00081744]. BMC Infect Dis. 2005;5:88.
Petersen PJ, Bradford PA. Effect of medium age and supplementation with the
biocatalytic oxygen-reducing agent oxyrase on in vitro activities of tigecycline
against recent clinical isolates. Antimicrob Agents Chemother.
2005;49:3910–3918.
Picazo JJ, Betriu C, Gomez M, Rodriguez-Avial I, Sanchez BA. In vitro activity
of tigecycline compared with other antimicrobial agents against recent clinical
isolates of methicillin-resistant Staphylococcus aureus. Proceedings of the 43rd
Annual Interscience Conference on Antimicrobial Agents and Chemotherapy;
September 14–17, 2003; Chicago, IL. Abstract E-1526.
Plowman R. The socioeconomic burden of hospital acquired infection. Euro
Surveill. 2000;5:49–50.
Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E; Tigecycline 200 Study
Group. Results of a multicenter, randomized, open-label efficacy and safety
study of two doses of tigecycline for complicated skin and skin structure
infections in hospitalized patients. Clin Ther. 2004;26:704–714.
Projan SJ. Preclinical pharmacology of GAR-936, a novel glycylcycline
antibacterial agent. Pharmacotherapy. 2000;20:219S–223S.
Tigecycline | outcomes review
Core Evidence 2006;1(3)Raghavan M, Linden PK. Newer treatment options for skin and soft tissue
infections. Drugs. 2004;64:1621–1642.
Reynolds R, Potz N; BSAC Working Party on Bacteraemia Isolates in the UK
and Eire. Activity of tigecycline against 2206 recent bacteremia isolates in the
UK and Eire. Proceedings of the 43rd Annual Interscience Conference on
Antimicrobial Agents and Chemotherapy; September 14–17, 2003; Chicago, IL.
Abstract E-1532.
Roblin PM, Hammerschlag MR. In vitro activity of GAR-936 against Chlamydia
pneumoniae and Chlamydia trachomatis. Int J Antimicrob Agents.
2000;16:61–63.
Sabol K, Patterson JE, Lewis JS 2nd, Owens A, Cadena J, Jorgensen JH.
Emergence of daptomycin resistance in Enterococcus faecium during
daptomycin therapy. Antimicrob Agents Chemother. 2005;49:1664–1665.
Sacchadinand S, Penn RL, Embil JM, et al. Efficacy and safety of tigecycline
monotherapy compared with vancomycin plus aztreonam in patients with
complicated skin and skin structure infections: results from a phase 3,
randomized, double-blind trial. Int J Infect Dis. 2005;9:251–261.
Shah PM. The need for new therapeutic agents: what is in the pipeline? Clin
Microbiol Infect. 2005;11(Suppl. 3):36–42.
Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-
infective agents for complicated intra-abdominal infections. Clin Infect Dis.
2003;37:997–1005.
Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis
and management of skin and soft-tissue infections. Clin Infect Dis.
2005;41:1373–1406.
Strahilevitz J, Rubinstein E. Novel agents for resistant Gram-positive infections
– a review. Int J Infect Dis. 2002;6:S38–S46.
Troy SM, Muralidharan G, Micalizzi M, Mojavarian P, Salacinski L, Raible D. The
effects of renal disease on the pharmacokinetics of tigecycline (GAR-936).
Proceedings of the 43rd Annual Interscience Conference on Antimicrobial
Agents and Chemotherapy; September 14–17, 2003; Chicago, IL. Abstract A-22.
US Congress Office of Technology Assessment. Impacts of antibiotic-resistant
bacteria. Washington, DC: US Government Printing Office; September 2005.
Publication No. OTA-H-629.
Wallace Jr RJ, Brown-Elliott BA, Crist CJ, Mann L, Wilson RW. Comparison of
the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with
those of tetracycline, minocycline, and doxycycline against isolates of
nontuberculous mycobacteria. Antimicrob Agents Chemother.
2002;46:3164–3167.
Wenzel RP. The antibiotic pipeline – challenges, costs, and values. N Engl J
Med. 2004;351:523–526.
Wilson P. Endemic, highly resistant Acinetobacter in the intensive care unit –
is tigecycline the answer? Clin Microbiol Infect. 2004;10(Suppl. 3):247
(Abstract P938).
Yu H, Mallick R, Weber DJ. Duration of antibiotic treatment in hospitalized
patients with complicated skin and skin structure infections (cSSSI): findings
from a clinical study comparing tigecycline and vancomycin/aztreonam. Poster
presented at: International Society for Pharmacoeconomics and Outcomes
Research, 10th Annual Meeting; May 15–18, 2005; Washington, DC. Poster
PIN3.
Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines: a comparative
review with the tetracyclines. Drugs. 2004;64:63–88.
Correspondence: Doris Peter, Core Medical Publishing, 445
Hamilton Avenue, Suite 1102, White Plains, New York, NY
10601, USA or at editor@coreevidence.com
Tigecycline | outcomes review
© 2006 Core Medical Publishing Limited 194